Answers are grounded in this paper and cite their sources.
Research on biomaterial-based tumor immunotherapy is booming; however, several challenges remain to be overcome to transition from experimental research to clinical application. Biomaterials have been optimized continuously and nanotechnology has achieved continuous progression, ensuring the development of more efficient biomaterials, thereby providing a platform and opportunity for breakthroughs in tumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: